Agropur Announces Closure Of Winnipeg Fluid Milk Plant

Apr 16, 2021

Agropur Cooperative announced it is closing its fluid milk plant in Winnipeg.

The plant’s operations will be transferred to other Agropur fluid milk facilities in Western Canada.

A total of 48 employees will be affected by the closure, planned for September 24, 2021.

Agropur says it is closing the plant in order to optimize its fluid milk manufacturing operations, adding given current market conditions, the company made a strategic decision to concentrate its fluid milk manufacturing operations for Western Canada at three other facilities, located in Burnaby and Victoria in British Columbia and Edmonton, Alberta.

"Unfortunately, the level of investment required to maintain the plant's competitiveness in the coming years was becoming too high. We are making this strategic decision to optimize our consumer milk network in Western Canada. This will help simplify our business model and ensure our competitiveness," said Émile Cordeau, CEO.

Agropur processes more than 6.6 billion litres of milk per year at its 33 plants across North America.

Click here to see more...

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.